NCT03719924 - Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

March 7, 2019

Primary Completion Date

April 15, 2024

Study Completion Date

September 29, 2024

Conditions

Squamous Cell Carcinoma

Interventions

DRUG

Onivyde

onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.

DRUG

Paclitaxel

Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15

Trial Locations (9)

Chu Amiens, Amiens

Institut Sainte Catherine, Avignon

Hopital Européen, Marseille

Ch Le Raincy, Montfermeil

Chu Saint Louis, Paris

Ch Perpignan, Perpignan

Chu de Poitiers, Poitiers

Chu Rouen, Rouen

Ch Duchenne, St-Malo